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Abstract
The diagnosis of invasive fungal disease remains challenging. The development of the European 
Organization for Research and Treatment of Cancer/Mycoses Study Group criteria has helped 
standardise diagnosis, yet PCR is excluded, a result of limited standardisation and concurrent 
clinical validation. In 2006, the European Aspergillus PCR Initiative working party of Interna-
tional Society of Human and Animal Mycoses was formed with the aim of establishing a standard 
for PCR methodology for the diagnosis of invasive aspergillosis, to attain an accurate clinical util-
ity of PCR and acceptance of PCR in future disease defining criteria. This manuscript will provide 
an overview of the standardisation process, before describing the potential samples available 
and the reasoning behind the choices made. It will summarise the key findings, provide the 
European Aspergillus PCR Initiative recommendations when testing whole blood and serum, and 
conclude with a synopsis of future European Aspergillus PCR Initiative perspectives and other 
key processes that will improve PCR based diagnosis.
© 2012 ACIN. Published by Elsevier España, S.L. All rights reserved.
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Hacia un estándar para Aspergillus PCR:  requisitos, proceso y resultados
Resumen
El diagnóstico de la enfermedad fúngica invasora sigue siendo un reto. El desarrollo de los cri-
terios del grupo de trabajo de la European Organization for Research and Treatment of Cancer/
Mycoses han ayudado a estandarizar el diagnóstico, sin embargo, la prueba de PCR (reacción en 
cadena de la polimerasa) se  excluye por su limitada estandarización y su concurrente validación 
clínica. En 2006, se formó la Iniciativa Europea Aspergillus-PCR, un grupo de trabajo de la Inter-
national Society of Human and Animal Mycoses que tenía como objetivo establecer una meto-
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Introduction
Molecular diagnostics brings many challenges to labora-
tories and clinicians. Orderly and systematic evaluation 
of analytical, laboratory and clinical validity and utility is 
required. Nowhere is this more evident than in the field 
of invasive fungal disease (IFD) diagnosis where traditional 
methods lack sensitivity to detect disease
The European Organization for Research and Treatment 
of Cancer/Mycoses Study Group (EORTC/MSG) consensus 
definitions use a combination of host, clinical and myco-
logical criteria to define IFD for the purpose of clinical tri-
als1. Whilst not designed for diagnosis of IFD in other clini-
cal settings, they are used increasingly. A proven diagnosis 
requires culture or histological demonstration of infection 
from a sterile site and, although yeasts, dimorphic fungi, 
and the occasional mould can be diagnosed by blood cul-
ture, invasive sampling procedures are required for inva-
sive aspergillosis (IA), usually in critically-ill patients and, 
as consequence, are seldom performed. The “less certain” 
diagnosis of probable IFD, relies on seeing “specific” radio-
logical evidence of a disease, i.e. those that are consistent 
with an IFD, in combination with mycological evidence 
in the form of demonstrating the presence of circulating 
biomarkers (Galactomannan [GM] or β-D-glucan [BDG]) or 
culture, in a patient with host factors.
PCR was not included as mycological evidence in the 
EORTC/MSG criteria despite significant research being 
done, particularly for IA2. Consequently, the value of PCR 
in aiding diagnosis is often overlooked. Exclusion from 
the EORTC/MSG criteria is less related to unsatisfactory 
performance but due to the fact that little standardisation 
had been attempted and, until recently, commercial alter-
natives were not available. Meta-analyses of GM, BDG and 
Aspergillus PCR in a clinical setting show similar sensitivi-
ties and specificities (BDG: 77% (95% CI: 67-84)/ 85% (95% 
CI: 79-89); GM: 78% (95% CI: 61-89)/81% (95% CI:72-88); 
PCR: 75% (95% CI: 54-88)/87% (95% CI: 78-93)3-5. The 
numerous publications relating to Aspergillus PCR reflect 
the continued scientific interest. There is methodological 
diversity with respect to PCR, though independent meta-
analysis shows its performance to be comparable to other 
biomarkers that use a standard commercial approach. 
Nevertheless, PCR provides similar pooled performance 
to commercial standardised antigen detection, suggesting 
that standardisation of an optimal PCR protocol could pro-
vide superior performance.
With this in mind, two national studies were conducted 
focussing on comparing PCR methodology for the detection 
of IFD, in particular Candida and Aspergillus PCR, as these 
are the most frequent causative agents for IFD6,7. The UK 
and Ireland fungal PCR consensus group found that Candida 
PCR methods provided comparable and satisfactory per-
formance, achieving a reproducible detection limit of 10 
organisms8. Performance of Aspergillus PCR methods was 
more variable, and even when two optimal protocols were 
assessed by multicentre evaluation performance of one 
assay varied with both PCR platform and sample type, and 
interactions between oligonucleotides and human (deoxyri-
bonucleic acid (DNA) were noted. Performance variability 
was also noted by the German/Austrian inter-laboratory 
comparison of PCR methods, and this occurred on both an 
intra and inter-laboratory scale9. These studies highlighted 
the need for standardisation, particularly if Fungal PCR was 
to gain widespread use outside of specialised molecular/
mycology centres.
In 2006, the European Aspergillus PCR Initiative (EAPCRI) 
working party of International Society of Human and Ani-
mal Mycoses was formed with the aim of establishing a 
standard for PCR methodology for the diagnosis of IA. With 
over 62 participating centres from 25 countries in four dif-
ferent continents (Europe, North and South America and 
Australia), the EAPCRI is now a global initiative with sev-
eral publications to its name10,11. This article will review 
the process and findings of the standardisation process for 
Aspergillus PCR and attempt to describe the differences 
when using different sample types.
PCR standardisation – procedural overview
Before implementing any test, it is essential to understand 
both the incidence and pathology of disease, and the impact 
on sample selection. These factors affect the amount and 
specific target within this specimen. On agreeing a sample 
type it is important to consider how best to evaluate current 
methods and understand the individual stages the testing 
process that may impact on assay efficiency. This requires 
the evaluation of relevant individual stages as well as of the 
entire process. In the initial stages of the evaluation, logisti-
cal and ethical issues mean it is unlikely that any samples 
will come directly from infected patients. The use of animal 
models for large scale multi-centre investigations is not pos-
sible due the number and volume of samples required. Conse-
quently, simulated samples are usually used, and the Quality 
Control (QC) panel should contain burdens and targets rep-
resentative of the clinical scenario, as well as both negative 
and positive samples. The sample matrix should be screened 
for contamination before use and, if clean, the panel should 
be developed using good aseptic and molecular techniques, if 
necessary using clean room facilities (e.g. laminar air flow) to 
prevent preparation-borne contamination12.
dología estándar de la PCR para el diagnóstico de la aspergilosis invasora y conseguir la utilidad 
clínica precisa de esta prueba para definir los criterios de la enfermedad. Este estudio ofrece 
una visión general del proceso de estandarización, describe las posibles muestras disponibles y el 
razonamiento en el que se basaron las decisiones tomadas. Resume las principales conclusiones, 
ofrece las recomendaciones de la Iniciativa Europea de Aspergillus PCR en el análisis de de la 
sangre total y el suero, y concluye con una sinopsis de las futuras perspectivas europeas de la 
iniciativa Aspergillus y los otros procesos clave que mejorarán el diagnóstico basado en PCR.
© 2012 ACIN. Publicado por Elsevier España, S.L. Todos los derechos reservados.
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Once a QC panel is prepared, it should be evaluated to 
determine expediency prior to storage to minimise degra-
dation. The panel should be distributed in a way that main-
tains the storage status and sample anonymity. Problems 
with distribution should be recorded, particularly if they 
affect the panel status and the individual recipient should 
relay this back to the distributor. The panel should be 
stored by the recipient as agreed until testing, using stand-
ard protocols for that centre, and meeting any pre-test 
conditions set by the distributor (e.g. testing time, internal 
control or replicate testing). In addition to the results, 
technical details concerning the entire molecular process 
should be returned. Overall multi-centre results should be 
compared to the original expediency test to establish if the 
panel has withstood the storage and distribution process. 
Blinded meta-regression analysis of results to determine 
assay performance and, both positive and negative, associ-
ations with individual technical steps should be performed. 
Any findings will form the basis of technical recommenda-
tions to be conveyed to participants and assessed by the 
distribution of further anonymous panels.
On return of the results and prerequisite technical 
information, blinded analysis will be performed for centres 
following recommendations designed to improve perform-
ance and compared to previous panels or to centres not 
following the recommendations.
If performance associated with the recommendations is 
shown to be superior then these are further assessed using 
specimens derived from animal models of the specific dis-
ease, ahead of any multi-centre clinical evaluation using 
patient samples.
Standardisation of Aspergillus PCR – the need
With the first manuscripts describing the use of PCR to aid in 
the diagnosis of IA being published almost two decades ago, it 
is surely time to finally decide whether PCR is clinically use-
ful or not. GM ELISA has been in use for a similar period, is 
widely used for screening, diagnosis and monitoring of thera-
peutic response, and methodological standardisation has been 
achieved by a single manufacturer adopting a commercial QC 
of the entire manufacturing process. By contrast PCR tests are 
mostly “in house” tests. Clearly methodological standardisation 
is needed13. The only way to accurately determine the clinical 
utility of PCR is through a prospective multi-centre study of 
substantial size, and the potential role of PCR can be deter-
mined through standardisation which does not exclude com-
mercial participation, providing a much needed additional test 
for inclusion into a diagnostic strategy. Once this occurs, PCR 
can take its place among the tests accepted for defining IFD.
The European Aspergillus PCR Initiative  
structure
Initially, the EAPCRI (http://www.eapcri.eu) created two 
working groups with extensive experience in laboratory (labo-
ratory working group) and clinical (clinical working group) 
diagnosis of IA. Membership to these groups initially relied 
on pairing clinicians and scientists from the same centre. 
Both working groups had a lead member who represented the 
working parties on the steering committee, along with the 
chair of the organisation, whose role was to direct the EAPCRI 
process. However, it quickly became apparent that the labo-
ratory working group programme required expansion and so 
additional test centres were recruited to help develop and 
test the protocols required for standardisation. The amount 
of information generated was such that a statistical working 
party was formed to help analyse the results.
Potential specimens
A literature review of the pathology of IA, the range of 
specimens tested, and how these could affect the manage-
ment of patients was undertaken before any laboratory 
evaluation could take place.
Respiratory Samples
Since IA most commonly affects the lungs, a respiratory speci-
men seems the obvious choice to permit early detection of the 
organism. However, sputum is of limited use, associated with 
higher levels of airway contamination and can be difficult to 
process, whereas bronchoalveolar lavage (BAL) has great 
clinical relevance but is a relatively invasive procedure. The 
performance of PCR in BAL specimens is comparable to those 
for GM, BDG and PCR performed on serum or blood. A meta-
analysis of Aspergillus PCR when testing BAL specimens pro-
vided pooled sensitivity and specificity of 79% and 94%, similar 
to the sensitivities and specificities generated by respective 
meta-analyses of GM, BDG and Aspergillus PCR testing blood 
specimens3-5,14. However, these observations do not take into 
account the temporal relationships of positivity, nor which 
is the earliest marker of disease, which is important as the 
prognosis is dramatically improved by early treatment led 
by an earlier diagnosis15. Aspergillus was detected in blood 
samples of cases of IPA at a later stage than was found for 
BAL16. However, obtaining BAL specimens may not be possible 
for a variety of reasons, including thrombocytopenia. Moreo-
ver, Aspergillus conidia may be inhaled continually, providing 
multiple time points for initiation of disease, thereby neces-
sitating the need for frequent sampling but also increasing 
the possibility of false positivity by detecting Aspergillus 
airway contamination or colonisation. Although 25% of BAL 
specimens from healthy volunteers were PCR positive17, the 
meta-analysis showed that specificity was not significantly 
affected in a clinical setting14. It is likely that PCR positivity 
in BAL specimens taken from areas of radiologically confirmed 
infection will have greater clinical significance because of 
higher fungal burdens16. So, to confirm a diagnosis of IA at 
a specific time point, the testing of computed tomography 
directed BAL specimens may provide the earliest opportunity 
for genus or species level detection.
Blood samples
As the incidence of IA is relative low, (<10%) even among 
those cohorts considered to be at high risk, it can be argued 
that infrequent testing of BAL samples is not an optimal 
strategy. With a low pre-test probability of disease, assays 
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are better suited to excluding disease, relying on a high 
sensitivity and negative predictive value, in other words 
“screening”. This approach also reduces the need for unnec-
essary empirical therapy, thus reducing both cost and anti-
fungal associated patient toxicity18. Taking isolated samples 
can result in low positivity rates, and this is compounded by 
the low fungal burdens in certain sample types. Even when a 
sample is positive, a second sample is needed for confirma-
tion to improve the positive predictive value of PCR5. Blood 
is readily obtained but it is important to consider the poten-
tial targets and their route of entry in to the circulatory 
system (Fig. 1). Normally, alveolar macrophages would clear 
inhaled conidia, but failure to do so would result in germina-
tion and hyphal production that would have been countered 
by the actions of the neutrophil, but these cells are absent 
during neutropenia19. Infection will ensue through tissue 
invasion and angioinvasion, and may coincide with the 
release of fungal elements such as GM and β-D-glucan and 
possibly even DNA. If unchecked, infection can then pro-
ceed to disease with tissue destruction, haemorrhage and 
vascular infarction providing the typical early radiological 
nodule or halo signs. Dissemination may also ensue. This 
simplistic description of disease would indicate that any 
fungal target in blood would be dependent on angioinvasion, 
with potential positivity being dependent on burden, itself 
being reliant on the degree of angioinvasion. It is also pos-
sible that conidia phagocytosed within macrophages could 
be detected in the circulation shortly after exposure to the 
organism, which is suggested by the detection of inhaled 
labelled micro-particles in the bloodstream20. Detecting this 
potential source could help pre-empt disease, although false 
positivity could occur, as not every high-risk patient exposed 
to Aspergillus conidia develops IA. Nevertheless, knowing 
that a patient at high-risk of developing IA has become 
infected, to a degree, provides clinically useful information, 
particularly if combined with host factors (prolonged steroid 
use or neutropenia, allogeneic stem cell transplantation, 
graft versus host disease, genetic susceptibility to disease).
The actual source of DNA within the circulation is yet 
to be determined. Blood cultures seldom yield Aspergillus 
in cases of IA, yet if seeded, Aspergillus will grow in these 
cultures, indicating a non-viable source in blood21. Opposing 
this is the fact that the disease disseminates via the circula-
tion, and for this to occur a viable organism must be avail-
able. Morton et al. recently showed that Aspergillus would 
not grow or replicate in whole blood, and it is possible that, 
unlike candidaemia, where the yeast is actively growing and 
budding, Aspergillus enters the circulation but remains rela-
tively inactive until it reaches its tissue destination22. Con-
sequently, the circulatory burden of the mould is likely to 
be well below the detection limits of current blood culture 
systems. Non-viable targets, including hyphae damaged by 
platelet attachment23 and fungal cells phagocytosed within 
leukocytes probably provide a cell associated DNA source, 
and free circulating DNA (DNAaemia) will be present when 
released through the actions of the immune system. DNAae-
mia could also be influenced by antifungal therapy through 
its actions on the fungal cell wall/membrane, artificially 
increasing the DNA burden despite an efficient therapeutic 
response. In effectively treated cases, this effect would be 
temporary, as decreasing burden and concomitant rapid 
circulatory clearance of DNA should result in decreasing 
burdens. These different targets (free and cell associated 
DNA) would be found in different components of blood, cell 
associated DNA would be associated with the leukocytes, if 
present, whereas free DNA would be found in the serum or 
plasma, requiring different DNA extraction techniques.
Other samples
Haematogenous transfer can lead to disseminated disease 
infecting organs and other anatomical structures. This is 
why histological diagnosis remains the gold standard for 
diagnosis, but the invasive procedures necessary to obtain 
samples can be difficult during life. Moreover, PCR testing 
of these samples is limited and these specimens are usually 
obtained once, only permitting a diagnostic approach. It 
is of paramount importance to digest the surrounding tis-
sue efficiently when testing tissue specimens in order that 
invading hyphae can be targeted. Providing QC for these 
processes is difficult as developing simulated control sam-
ples is limited to specimens obtained from animal infection 
models or previously tested clinical material.
With cerebral disease, PCR testing of cerebrospinal fluid 
may be productive, and several studies have shown suc-
cessful applications24,25. Again testing is limited to diagno-
sis, as studies and specimens are limited. It is unclear what 
the actual target within the cerebrospinal fluid sample is, 
organism or free DNA.
In using PCR to diagnose disseminated disease, it can 
be argued that the clinical utility of PCR testing will be 
minimal, the disease is advanced and patient prognosis will 
be worse compared to testing samples capable of detecting 
the organism at exposure or infection. However, diagnosis 
still has value when the disease continues to progress 
despite antifungal therapy, as it might be due to other 
moulds such as those belonging to the Mucorales. In this 
scenario Aspergillus PCR testing should remain negative 
and pan-fungal PCR or PCR specific to the other aetiology 
would be required to confirm IFD.
The European Aspergillus PCR Initiative  
strategy
At the start of the EAPCRI it was decided that using PCR 
for screening provided the optimal strategy which obvi-
ously excluded the use of BAL, cerebrospinal fluid or tissue 
samples, and focussed on testing blood. With the potential 
targets located either in the cells or in the plasma/serum it 
was decided to initially focus on whole blood to pursue the 
goal of EAPCRI as there was a need for greater standardisa-
tion of DNA extraction methods. On completing this process, 
it was repeated for serum, with plasma being reserved for 
future investigations.
Whole blood standardisation10
The next stage was to evaluate methods currently in use. 
For any molecular procedure there are two basic steps; first, 
nucleic acid extraction and then amplification. While it is 
important to evaluate the combined performance of these 
68 P.L.White et al
processes it is also important to determine the performance 
of the individual processes; this overcomes the potential 
effect of combining a poor extraction technique with an 
optimal PCR test, leading to poor PCR performance.
The first EAPCRI panel was developed to do both, and 
comprised a panel of quantified A. fumigatus genomic DNA 
to evaluate PCR alone, and a whole blood panel seeded with 
different concentrations of A. fumigatus conidia to evaluate 
DNA extraction and PCR10. Although conidia are unlikely to 
be involved in the invasive disease process, the panel needed 
to be consistently quantifiable between centres and it was 
not possible to accurately quantify multinucleate hyphae. To 
maintain the goal of a screening assay with a high negative 
predictive value, the panel was designed to determine limits 
of detection and overall sensitivity, rather than specificity, 
and a designated threshold for detection was set. Participants 
were asked to return results and also supply technical infor-
mation for both nucleic acid extraction and PCR amplification 
to allow subsequent analysis. All data and statistical analyses 
were performed in a blinded fashion to anonymise the iden-
tity of the participant and allow unbiased evaluation.
The DNA panel showed that 90% of participating centres 
attained the designated threshold. However, when DNA 
extraction was combined with PCR only nine (41%) of 22 cen-
tres reached the same level of performance, indicating that 
DNA extraction was the rate-limiting step. Enhanced per-
Figure 1 Potential Aspergillus DNA sources and targets within the circulation.
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formance was noted with centres processing the entire 3mL 
sample and the use of “bead-beating” to lyse fungal cells; 
these recommendations were provided to every recipient of 
the second panel. This time Aspergillus PCR performance 
was significantly improved compared to the first round, and 
performance for centres compliant with the recommenda-
tions provided showed further improvements, with a sensi-
tivity and specificity of 88.7% and 91.6%, respectively. Meta-
regression analysis showed positive associations between 
sensitivity and compliant methods, the use of white cell 
lysis, “bead-beating”, and the incorporation of an internal 
control PCR. A negative association between sensitivity and 
the use of elution volumes >100 µL was also noted. These 
formed the basis of the recommendations for Aspergillus 
PCR testing of whole blood samples (Table 1.)
Serum standardisation11
On completing whole blood PCR standardisation it was 
decided to evaluate serum samples. Serum PCR, theoreti-
cally, requires less standardisation as there are no human 
blood cells, fungal cell lysis is no longer required, thus 
minimising any additional processing steps, and the poten-
tial target was likely to be free circulating DNA (DNAae-
mia), yet the sample still allows a screening strategy to be 
employed11. It was hypothesised that when targeting such 
Table 1 European Aspergillus PCR Initiative recommendations for PCR testing of whole blood. Adapted from J Clin 
Microbiol.2010;48:1231-40.10
Recommendation Evidence base
Only use EDTA-anticoagulated whole  Heparin has been associated with PCR inhibition31 and sodium citrate has been 
blood specimens shown to be contamination with Aspergillus32  
 Please note: batches of EDTA blood collection tubes have been contaminated with  
 Aspergillus DNA and screening of all reagents, including vacutainers, should be  
 performed prior to clinical use33
Use a minimum of 3mL sample Two thirds of centres attaining the designated threshold in the EAPCRI studies  
 used 3 mL of sample In an analytical study using lower volumes was associated  
 with impaired reproducibility of detection34
Red cell lysis improves performance >Two thirds of centres attaining the designated threshold in the EAPCRI studies 
 used red cell lysis. In an analytical study not using red cell lysis resulted in a  
 significant delay in Cq values34
The use of white cell lysis is critical A significant positive association between sensitivity and white cell lysis was  
 determined (P:0.018)
Fungal cells should be lysed using  A significant positive association between sensitivity and bead-beating was 
bead-beating determined (P:0.033). It is also cheaper and quicker than an enzymatic approach  
 and as has been shown to effective on hyphae and conidia35
Screen all reagents before using for  Contamination of various reagents used in molecular biology with fungal DNA has 
routine clinical diagnosis been noted33,36,37
Use positive and negative extraction  Good molecular practice to monitor for inter-assay variation
controls 
Elute DNA in <100µL A significant negative association between sensitivity and elution volumes >100  
 µL was determined (P:0.035)
PCR testing should be performed  Although most PCR assays perform to a similar standard, the fungal burden in 
in duplicate clinical samples is likely to be at levels close to or beyond the reproducible limit  
 of detection, consequently replicate testing may be necessary to avoid the  
 reporting of false negative results
An internal control PCR should  Good molecular practice to monitor for PCR inhibition and avoid reporting false 
be performed negative results
The internal control should generate  If the burden of internal control target is much higher than the target the affects 
a Cq value typical to values seen of inhibition may be less evident, potentially resulting in only slight Cq delays of 
when testing Aspergillus positive the internal control. As the fungal burden in blood is at the limit of QPCR  
clinical samples detection any delays may result in false negative results
Human DNA should not be used for  The amount of human DNA will vary per specimen, consequently PCR amplification 
an internal control target is purely qualitative and it is not possible to have a reference Cq value from which  
 inhibition can be determined. The burden of human DNA is likely to be far greater  
 than the Aspergillus DNA and may not be as affected by inhibition (See above)
DNA: deoxyribonucleic acid; EAPCRI: European Aspergillus PCR Initiative; EDTA: ethylenediaminetetraacetic acid;  
QPCR: quantitative polymerase chain reaction.
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a source, simple nucleic acid extraction protocols could be 
used, with commercial kits providing greater standardisation 
and QC; this would be a necessary prerequisite if PCR was 
to enjoy widespread use outside specialist molecular mycol-
ogy laboratories. Following the algorithm described above, 
a panel of serum samples loaded with varying amounts of A. 
fumigatus genomic DNA was distributed to laboratory work-
ing group members to evaluate protocols currently being 
used. Again the panel was designed to principally determine 
analytical sensitivity, both technical information and results 
were returned, and data analysis was performed blinded to 
the identity of the participant. As the previous study had 
shown DNA extraction to be the rate limiting state, a panel 
to evaluate PCR alone was not included.
Initially, when evaluating whole blood, less than half of 
methods were able to attain the designated threshold. For 
serum testing, this figure rose to 82.8% (24/29), confirm-
ing the hypothesis that methods testing serum required less 
standardisation. Overall sensitivity (86.1%) and specificity 
(93.6%) values were comparable to those for whole blood 
PCR compliant with EAPCRI recommendations. ROC analysis 
showed excellent performance, with area under the curve of 
0.915, and optimal performance using a Cq threshold of 43 
cycles, in keeping with a previous report26. Therefore, it was 
deemed unnecessary to evaluate procedural recommenda-
tions. Instead, meta-regression analysis was performed using 
the existing data. Significant positive associations were noted 
between sensitivity and the use of larger sample volumes 
(≥0.5 mL) (P=.023), an internal control PCR (P=.029) and PCR 
assays targeting the ITS region (P=.013). Significant nega-
tive associations were noted between sensitivity and elut-
ing nucleic acid in volumes >100 µL (P=.003) and using PCR 
assays targeting mitochondrial regions (P=.010). However, 
associations between sensitivity and specific genomic regions, 
Table 2 European Aspergillus PCR Initiative recommendations for PCR testing of serum11
Recommendation Evidence base
Use a minimum of 0.5 mL sample A significant positive association between sensitivity and sample volume was  
 determined (P:0.023)
Most commercially available  Twenty-eight of 29 protocols evaluated were able to reach the designated 
nucleic acid extraction systems  threshold of detection on at least one occasion, generating a threshold 
can be used to extract Aspergillus  positivity rate of 91.5% 
DNA using the protocols as  
described by the manufacturer 
Screen all reagents, including  Contamination of various reagents used in molecular biology with fungal DNA has 
commercially sourced kits and  been noted33,36,37 
reagents, before using for routine  
clinical diagnosis 
Use methods specific for testing  Methods specifically designed to test whole blood were not able to efficiently 
serum process serum samples
Use positive and negative  Good molecular practice to monitor for inter-assay variation 
extraction controls 
Elute DNA in <100 µL A significant negative association between sensitivity and elution volumes >100 µL 
 was determined (P:0.003)
PCR testing should be performed  Although most PCR assays perform to a similar standard, the fungal burden in 
in duplicate clinical samples is likely to be at levels close to or beyond the reproducible limit  
 of detection, consequently replicate testing may be necessary to avoid the reporting  
 of false negative results
An internal control PCR should be Good molecular practice to monitor for PCR inhibition and avoid reporting false 
performed, and for serum testing can negative results. By incorporating the internal control at the start of the extraction 
be included at the start of the process process the efficiency of extraction for individual samples can also be monitored
The internal control should generate If the burden of internal control target is much higher than the target the affects of 
a Cq value typical to values seen inhibition may be less evident, potentially resulting in only slight Cq delays of the 
when testing Aspergillus positive internal control. As the fungal burden in blood is at the limit of QPCR detection any 
clinical samples delays may result in false negative results
Human DNA should not be used  The amount of human DNA will vary per specimen, consequently PCR amplification is 
for an internal control target purely qualitative and it is not possible to have a reference Cq value from which 
inhibition can be determined
Use a PCR positivity threshold  This provides the greatest degree of diagnostic accuracy (DOR of 105) 
of 43 cycles
DNA: deoxyribonucleic acid; QPCR: quantitative polymerase chain reaction.
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whether positive or negative, should be interpreted with 
caution as the number of assays targeting the regions stated 
were limited and reaction kinetics will vary according to the 
assay design and optimisation, and performance may not be 
directly associated with the target gene but exclusive to the 
individual assay11. These results were the basis for the EAPCRI 
recommendations for PCR testing of serum (Table 2).
Future considerations
The obvious next step for the EAPCRI would be to test 
plasma, as this is the complete liquid component of blood 
without the cell, and includes the clotting factors. Theoreti-
cally, both serum and plasma types contain the same target 
(DNAaemia), but the blood clot formed prior to obtaining 
serum could, in addition to trapping human erythrocytes, 
leukocytes, and any fungal cells potentially reduce the 
amount of free DNA in the sample; this would not happen 
in plasma. Evaluating the effect of these different sample 
types on the mechanics of any nucleic acid extraction tech-
nique would be relatively straightforward through testing 
plasma and serum samples loaded with the same fungal DNA 
burdens after the separation of the required blood fractions. 
However, this would not assess the affect of clot formation 
on the DNA burden. This could be assessed using simulated 
samples, spiking blood collection tubes with Aspergillus DNA, 
possibly prior to drawing blood, but certainly prior to clot 
formation, and for plasma testing by spiking the ethylenedi-
aminetetraacetic acid blood tube prior to fractionation.
For confirming the diagnosis, specimens require more 
invasive procedures, and obtaining these samples must be 
weighed up against the potential benefit to the patient, 
and whether a PCR diagnosis will alter patient management 
or outcome. For instance, if a patient is already receiving 
antifungal therapy and is responding, then obtaining a deep 
tissue sample for PCR testing may not lead to a change in 
therapy or alter the outcome. Post-mortem testing could 
confirm a diagnosis, but there is no need for rapid diagnosis 
as a histopathological/mycological approach will suffice. 
The enhanced sensitivity and specificity provided by real-
time PCR provides the opportunity to pre-empt infection 
from becoming manifest disease, thereby helping improve 
the patient prognosis. Currently, since most cases of IA 
begin in the lung, obtaining a BAL specimen is the only way 
of attaining an appropriate specimen for diagnosis. Estab-
lishing testing panels with this specimen presents several 
logistic hurdles, including sourcing “willing” volunteers to 
provide sufficient BAL samples, and overcoming potential 
airway contamination leading to Aspergillus positive BAL 
material. The potential of evaluating a simulated BAL 
specimen is currently being pursued.
The EAPCRI also recognises the contributions of other 
organisations trying to improve the quality of molecular 
diagnosis and lead to greater standardisation. The Invasive 
Aspergillosis Animal model group are developing standard-
ised in vivo models of IA to provide representative pathologi-
cal samples, while the Aspergillus Technology Consortium 
is developing a bank of samples from patients with IA to 
provide source material for evaluating diagnostic tests.
Commercial assays are now becoming available, and pre-
liminary clinical validation looks promising, although patient 
numbers are limited when compared to many evaluations 
of “in-house” protocols27,28. From the beginning the EAPCRI 
has sought commercial collaboration and by participation 
in testing EAPCRI QC panels, commercial partners ensure 
their analytical performance is comparable to well validated 
methods. The commercial production and the independent 
analytical performance validation of commercial assays 
provide the opportunity for Aspergillus PCR to be performed 
outside specialist molecular mycology laboratories.
The minimum information for publication of quantitative 
real-time PCR experiments (MIQE) guidelines were published as 
a guide to researchers as to the minimum information required 
in manuscripts describing real-time PCR experiments29, and 
this has recently been applied specifically to an Aspergillus 
PCR protocol30. While we fully support this guidance, it is 
important to add that the MIQE guidelines were published to 
encourage researchers to provide the technical information 
necessary for readers to compare and replicate assays. It is 
unwise to assume that these recommendations have been fol-
lowed in papers published before these guidelines appeared 
however, limitations in space often precludes the inclusion of 
extensive technical information, even if assay optimisation and 
analytical evaluation has been performed as described by the 
current MIQE guidelines. There needs to be direct comparisons 
of the recent MIQE designed Aspergillus PCR assay with other 
previously well validated assays before concluding that it will 
provide improved clinical performance, particularly when our 
research shows DNA extraction to be rate-limiting10.
In conclusion, the EAPCRI has made significant steps in 
developing a standard for Aspergillus PCR, but recognises that 
the process will not be finished until the clinical utility has 
been established in formal clinical trials. Currently, samples 
for PCR testing are being taken in two prospective trials, 
one comparing pre-emptive and empirical strategies (EORTC 
65091-06093: ClinicalTrials.gov Identifier: NCT01288378), and 
the other on the prevention of invasive fungal infections in sub-
jects receiving chemotherapy for acute lymphoblastic leukae-
mia (Ambiguard: ClinicalTrials.gov Identifier: NCT01259713). 
Methodological recommendations are being evaluated using 
non-simulated animal model material, and collaborations 
with Invasive Aspergillosis Animal model group continue. On 
completion, it is hoped that PCR will have attained sufficient 
standardisation and validation to be included in the EORTC/
MSG definitions of IFD.
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